Immunomodulation and Regeneration: The Role of Stem Cell Therapy in Autoimmune Disorders

Autoimmune diseases arise from a breakdown of immunological self-tolerance, in which the immune system mistakes host tissues for foreign threats and mounts a sustained, damaging attack. Collectively they affect close to one in ten people and impose a substantial and rising chronic-disease burden. Conventional management relies on broad immunosuppressants and, more recently, targeted biologics. Although these agents can control disease activity, they act by dampening immunity rather than restoring balance, requiring indefinite treatment, carrying cumulative infection and malignancy risks and rarely inducing durable, drug-free remission. Stem cell therapy has emerged as a conceptually different strategy that aims to reset or recalibrate the immune system while supporting repair of damaged tissue. Two approaches dominate the field. Hematopoietic Stem Cell Transplantation (HSCT) eliminates the autoreactive immune repertoire through conditioning chemotherapy and reconstitutes a naive, self-tolerant immune system. Mesenchymal Stem Cells (MSCs), by contrast, are potent immunomodulators that suppress effector lymphocytes, expand regulatory T cells and secrete anti-inflammatory and reparative factors without the toxicity of myeloablation. Clinical evidence now spans multiple sclerosis, systemic lupus erythematosus, rheumatoid arthritis, Crohn’s disease and type 1 diabetes, with some of the strongest randomized evidence supporting autologous HSCT in aggressive relapsing-remitting multiple sclerosis, while local MSC therapy represents the most developed, though recently contested, evidence in perianal fistulizing Crohn’s disease. This narrative review summarizes the biological rationale, mechanisms of action, disease-specific clinical outcomes, safety considerations and the regulatory and translational challenges that stand between promising early results and standard-of-care adoption.